hydroxychloroquine has been researched along with Cholera Infantum in 16 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the usefulness of hydroxychloroquine (HCQ) dose-loading to increase the percentage of responders or rate of response in treating rheumatoid arthritis (RA)." | 9.09 | Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. ( Baethge, B; Botstein, GR; Caldwell, J; Dietz, F; Ettlinger, R; Furst, DE; Golden, HE; Lindsley, H; McLaughlin, GE; Moreland, LW; Roberts, WN; Rooney, TW; Rothschild, B; Sack, M; Sebba, AI; Weisman, M; Welch, KE; Yocum, D, 1999) |
| "Eighty patients with active rheumatoid arthritis (RA) entered a double-blind randomized study of 24 weeks duration, to compare the efficacy and toxicity of hydroxychloroquine, dapsone, and a combination of both drugs in treatment of RA." | 9.07 | A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis. ( Christensen, L; Haar, D; Hansen, TM; Rasmussen, KJ; Sølvkjaer, M; Unger, B, 1993) |
| "A dose-response relationship for hydroxychloroquine (HCQ), in terms of the proportion of patients achieving the Paulus 20% criteria for improvement, had previously been observed in patients with rheumatoid arthritis (RA) receiving a 6-week loading regimen of 400, 800, or 1,200 mg HCQ daily." | 7.71 | Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. ( Baethge, BA; Botstein, GR; Caldwell, J; Dietz, F; Ettlinger, R; Furst, DE; Gibbs, JP; Golden, HE; Lindsley, H; McLaughlin, GE; Moreland, LW; Munster, T; Roberts, WN; Rooney, TW; Rothschild, B; Sack, M; Sebba, AI; Shen, D; Weisman, M; Welch, KE; Yocum, D, 2002) |
| "To investigate the usefulness of hydroxychloroquine (HCQ) dose-loading to increase the percentage of responders or rate of response in treating rheumatoid arthritis (RA)." | 5.09 | Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. ( Baethge, B; Botstein, GR; Caldwell, J; Dietz, F; Ettlinger, R; Furst, DE; Golden, HE; Lindsley, H; McLaughlin, GE; Moreland, LW; Roberts, WN; Rooney, TW; Rothschild, B; Sack, M; Sebba, AI; Weisman, M; Welch, KE; Yocum, D, 1999) |
| "Eighty patients with active rheumatoid arthritis (RA) entered a double-blind randomized study of 24 weeks duration, to compare the efficacy and toxicity of hydroxychloroquine, dapsone, and a combination of both drugs in treatment of RA." | 5.07 | A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis. ( Christensen, L; Haar, D; Hansen, TM; Rasmussen, KJ; Sølvkjaer, M; Unger, B, 1993) |
| "A dose-response relationship for hydroxychloroquine (HCQ), in terms of the proportion of patients achieving the Paulus 20% criteria for improvement, had previously been observed in patients with rheumatoid arthritis (RA) receiving a 6-week loading regimen of 400, 800, or 1,200 mg HCQ daily." | 3.71 | Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. ( Baethge, BA; Botstein, GR; Caldwell, J; Dietz, F; Ettlinger, R; Furst, DE; Gibbs, JP; Golden, HE; Lindsley, H; McLaughlin, GE; Moreland, LW; Munster, T; Roberts, WN; Rooney, TW; Rothschild, B; Sack, M; Sebba, AI; Shen, D; Weisman, M; Welch, KE; Yocum, D, 2002) |
| "The main aim of this study was to examine the differences between triple therapy (T: SSZ and HCQ added to MTX) and etanercept (E) added to MTX with regard to the infectious and gastrointestinal (GI) adverse events (AEs) reported in The Rheumatoid Arthritis Comparison of Active Therapies Trial." | 2.84 | Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events. ( Brophy, MT; Chang, BH; Hannagan, K; O'Dell, JR; Quach, LT; Soe Thwin, S, 2017) |
| "To evaluate rates on the adverse side effect and discontinuation of second-line drugs frequently used in the treatment of rheumatoid arthritis (RA)." | 1.31 | [Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs]. ( Jiang, L; Ni, L; Zhao, N, 2002) |
| "A case of acrodermatitis enteropathica is presented that is the first to manifest punctal stenosis, the fourth to show corneal changes, and the sixth to survive into adulthood." | 1.25 | Eye manifestations in acrodermatitis enteropathica. ( Felker, GV; Ide, CH; Matta, CS, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (31.25) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Endo, Y | 1 |
| Koga, T | 1 |
| Umeda, M | 1 |
| Furukawa, K | 1 |
| Sasaki, D | 1 |
| Yanagihara, K | 1 |
| Kawakami, A | 1 |
| Alser, O | 1 |
| Mokhtari, A | 1 |
| Naar, L | 1 |
| Langeveld, K | 1 |
| Breen, KA | 1 |
| El Moheb, M | 1 |
| Kapoen, C | 1 |
| Gaitanidis, A | 1 |
| Christensen, MA | 1 |
| Maurer, LR | 1 |
| Mashbari, H | 1 |
| Bankhead-Kendall, B | 1 |
| Parks, J | 1 |
| Fawley, J | 1 |
| Saillant, N | 1 |
| Mendoza, A | 1 |
| Paranjape, C | 1 |
| Fagenholz, P | 1 |
| King, D | 1 |
| Lee, J | 1 |
| Farhat, MR | 1 |
| Velmahos, GC | 1 |
| Kaafarani, HMA | 1 |
| Quach, LT | 1 |
| Chang, BH | 1 |
| Brophy, MT | 1 |
| Soe Thwin, S | 1 |
| Hannagan, K | 1 |
| O'Dell, JR | 1 |
| Tang, C | 1 |
| Godfrey, T | 1 |
| Stawell, R | 1 |
| Nikpour, M | 1 |
| Munster, T | 1 |
| Gibbs, JP | 1 |
| Shen, D | 1 |
| Baethge, BA | 1 |
| Botstein, GR | 2 |
| Caldwell, J | 2 |
| Dietz, F | 2 |
| Ettlinger, R | 2 |
| Golden, HE | 2 |
| Lindsley, H | 2 |
| McLaughlin, GE | 2 |
| Moreland, LW | 2 |
| Roberts, WN | 2 |
| Rooney, TW | 2 |
| Rothschild, B | 2 |
| Sack, M | 2 |
| Sebba, AI | 2 |
| Weisman, M | 2 |
| Welch, KE | 2 |
| Yocum, D | 2 |
| Furst, DE | 2 |
| Jiang, L | 1 |
| Zhao, N | 1 |
| Ni, L | 1 |
| Schiemann, U | 1 |
| Kellner, H | 1 |
| Dancey, P | 1 |
| Constantin, E | 1 |
| Duffy, CM | 1 |
| Scuccimarri, R | 1 |
| Tweezer-Zaks, N | 1 |
| Ben-Horin, S | 1 |
| Schiby, G | 1 |
| Bank, I | 1 |
| Levi, Y | 1 |
| Livneh, A | 1 |
| Langevitz, P | 1 |
| Runge, LA | 1 |
| Haar, D | 1 |
| Sølvkjaer, M | 1 |
| Unger, B | 1 |
| Rasmussen, KJ | 1 |
| Christensen, L | 1 |
| Hansen, TM | 1 |
| Baethge, B | 1 |
| Matta, CS | 1 |
| Felker, GV | 1 |
| Ide, CH | 1 |
| Muirden, KD | 1 |
| Reich, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Non-ventilated Prone Positioning in the COVID-19 Population[NCT05957588] | 216 participants (Actual) | Interventional | 2021-10-01 | Completed | |||
| CSP #551 - Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy[NCT00405275] | 353 participants (Actual) | Interventional | 2007-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Average difference between 48-week and Baseline DAS28.~The Disease Activity Score for 28 Joints (DAS28) is a well-validated composite outcome measure ranging from 2-10 (higher scores indicating more disease) that incorporates a tender and swollen joint count of 28 joints, a laboratory measure of systemic inflammation (ESR) and a patient-reported general assessment of health on a visual analog scale (ranging from 0-10cm) all into one measure.~Low disease activity is defined as DAS28 ≤ 3.2 units." (NCT00405275)
Timeframe: 48 weeks after baseline assessment
| Intervention | units on a scale (Mean) |
|---|---|
| Triple | -2.12 |
| Etanercept | -2.29 |
4 reviews available for hydroxychloroquine and Cholera Infantum
| Article | Year |
|---|---|
Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects.
Topics: Antimalarials; Carbohydrate Metabolism; Cardiovascular Diseases; Chloroquine; Clinical Trials as Top | 2012 |
[Gastrointestinal side effects in the therapy of rheumatologic diseases].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic | 2002 |
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical T | 1986 |
[Acrodermatitis enteropathica. Clinical picture, life-saving treatment, therapy-induced blindness].
Topics: Acrodermatitis; Blindness; Gastrointestinal Diseases; Humans; Hydroxychloroquine; Infant; Iodoquinol | 1973 |
4 trials available for hydroxychloroquine and Cholera Infantum
| Article | Year |
|---|---|
Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events.
Topics: Abscess; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etaner | 2017 |
A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Arthrography; Blood Sedimentation; C-Reactive | 1993 |
Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response | 1999 |
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical T | 1986 |
9 other studies available for hydroxychloroquine and Cholera Infantum
| Article | Year |
|---|---|
Successful hydroxychloroquine treatment for familial Mediterranean fever in a Japanese patient with concurrent systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Asian People; Colchicine; Cytokines; Familial Mediterranean Fever; Fema | 2020 |
Multisystem outcomes and predictors of mortality in critically ill patients with COVID-19: Demographics and disease acuity matter more than comorbidities or treatment modalities.
Topics: Acute Kidney Injury; Adult; Age Factors; Aged; Aged, 80 and over; Antimalarials; Boston; Comorbidity | 2021 |
Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Eye Diseases; Gastrointestinal Dise | 2002 |
[Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs].
Topics: Adult; Anorexia; Antirheumatic Agents; Arthritis, Rheumatoid; Exanthema; Female; Gastrointestinal Di | 2002 |
Lupus cystitis in association with severe gastrointestinal manifestations in an adolescent.
Topics: Adolescent; Antirheumatic Agents; Azathioprine; Cystitis, Interstitial; Drug Therapy, Combination; F | 2005 |
Severe gastrointestinal inflammation in adult dermatomyositis: characterization of a novel clinical association.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Cyclophosphamide; Dermatomyositis; Fatal Outcome; Fem | 2006 |
Risk/benefit analysis of hydroxychloroquine sulfate treatment in rheumatoid arthritis.
Topics: Actuarial Analysis; Arthritis, Rheumatoid; Gastrointestinal Diseases; Gold; Humans; Hydroxychloroqui | 1983 |
Eye manifestations in acrodermatitis enteropathica.
Topics: Acrodermatitis; Aged; Anti-Bacterial Agents; Cornea; Diet Therapy; Eye Manifestations; Female; Gastr | 1975 |
[Corticotherapy in rheumatoid polyarthritis].
Topics: Adrenocorticotropic Hormone; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Betamethasone; C | 1971 |